People: Nanosphere Inc (NSPH.O)

NSPH.O on Consolidated Issue listed on NASDAQ Capital Market

0.24USD
23 Jan 2015
Change (% chg)

$-0.02 (-7.24%)
Prev Close
$0.26
Open
$0.26
Day's High
$0.27
Day's Low
$0.23
Volume
2,061,330
Avg. Vol
1,616,744
52-wk High
$2.69
52-wk Low
$0.23

Search Stocks

Summary

Name Age Since Current Position

Sheli Rosenberg

72 2013 Independent Chairman of the Board

Michael McGarrity

51 2013 President, Chief Executive Officer, Director

J. Roger Moody

46 Chief Financial Officer, Vice President - Finance & Administration, Treasurer, Secretary

Kenneth Bahk

40 2013 Chief Strategy Officer

Kristopher Wood

2014 Director

Gene Cartwright

60 2013 Independent Director

Andre de Bruin

67 2005 Independent Director

Erik Holmlin

46 2013 Independent Director

Lorin Randall

70 2008 Independent Director

Michael Ward

42 2013 Independent Director

Biographies

Name Description

Sheli Rosenberg

Ms. Sheli Z. Rosenberg is Independent Chairman of the Board of Nanosphere, Inc. In February 2013, Ms. Rosenberg was re-elected to company's Board of Directors and Chair of the Board. Ms. Rosenberg is the retired chief executive officer, president and vice chairwoman of Equity Group Investments, Inc. She joined Equity Group Investments, Inc. as General Counsel. She currently sits on the boards of four New York Stock Exchange listed corporations, including Equity LifeStyle Properties, Inc., Strategic Hotels and Resorts, Inc., Ventas, Inc. and Spirit Realty Capital, Inc., as well as NASDAQ listed Cellular Dynamics International, Inc. Ms. Rosenberg is a consultant to Skadden, Arps, Slate, Meagher & Flom LLP and served as Of Counsel from May 2010 to December 31, 2013. Ms. Rosenberg received her B.A. degree from Tufts University and her J.D. degree from Northwestern University.

Michael McGarrity

Mr. Michael K. McGarrity is President, Chief Executive Officer, Director of Nanosphere Inc. Mr.McGarrity joined Nanosphere in 2005 as Chief Marketing Officer. Mr. McGarrity, who has more than 18 years of sales and marketing experience in the medical device industry, joined Nanosphere after 13 years with Stryker Corporation. At Stryker, he served in leadership roles in marketing and strategic development, most recently as vice president of marketing for Stryker Instruments, where he also had executive general management responsibility for a newly created business focused on interventional pain management. Mr. McGarrity is a graduate of the University of Notre Dame and began his career in commercial banking in Chicago.

J. Roger Moody

Mr. J. Roger Moody, Jr., is Chief Financial Officer, Vice President - Finance & Administration, Treasurer, Secretary of Nanosphere Inc. Mr.Moody joined Nanosphere in 2007 as Chief Financial Officer and Vice President of Finance & Administration. He also serves as the Company’s Treasurer and Secretary. Mr.Moody has more than 20 years of experience in finance, corporate development and operations for high growth healthcare and technology companies. Previously, Mr. Moody spent six years at Medsn, a medical education company where he began as chief financial officer and was promoted to chief operating officer where he led Medsn’s United States and off-shore operations. Mr.Moody also served as chief financial officer and led corporate development for two private venture backed companies sold to strategic partners. Additionally, Mr. Moody provided mergers and acquisition and strategic advisory services to technology and healthcare companies for Volpe Brown Whelan & Company. Mr. Moody began his career at IBM. Mr.Moody received his B.S. from Syracuse University and his M.B.A. from the University of Chicago, Graduate School of Business.

Kenneth Bahk

Dr. Kenneth Bahk, Ph.D., is Chief Strategy Officer of Nanosphere, Inc. Dr. Bahk is a Director of Investments at Lurie Investments, focusing on investments in diagnostics and life sciences. Lurie Investments, together with its affiliates, is the holder ofNanosphere shares. Dr. Bahk currently serves on the board of directors of Aperion Biologics,Geneweave Biosciences and Viamet Pharmaceuticals. Dr. Bahk has been active in leadership positions for the premier diagnostic and molecular diagnostic organizations, and was Chair of Strategic Opportunities for the Association for Molecular Pathology, a committee charged with understanding key molecular diagnostic and pathology market drivers and trends. He is a member of the American Association of Clinical Chemistry, the American Society for Microbiology and the Association for Molecular Pathology. He received a Ph.D. in biochemistry and molecular biology and an MS in neurobiology and physiology from Northwestern University, and an MBA from the Kellogg School of Management.

Kristopher Wood

Mr. Kristopher A. Wood is Director of the Company. Mr. Wood is currently the sole member of Highline Partners, LLC, a consultancy through which he serves in the capacity of chief investment officer at Lurie Holdings, Inc. and as Special Advisor on strategic matters to New Page Corporation and its board of directors. Prior to forming Highline Partners, from 2009 to 2011, Mr. Wood served as head of strategy and corporate development at WorldColor Press, Inc. Mr. Wood served from 2007 to 2009 as an associate at MidOcean Partners, a private equity investment firm based in New York and London. Mr. Wood also served as chief acquisitions officer for Glenayre Inc. and as managing director for mergers and acquisitions and venture capital at Vertis Holdings, Inc. and its predecessor, Big Flower Holdings, Inc. He currently serves on the boards of directors for several privately-held companies. Mr. Wood received a BS in Economics from the Wharton School of the University of Pennsylvania.

Gene Cartwright

Dr. Gene Cartwright, Ph.D., is an Independent Director of Nanosphere, Inc., effective June 20, 2013. In January 2014, Dr. Cartwright was appointed chief executive officer of Guided Therapeutics, a privately held cancer diagnostics company. From March 2008 through March 2013, Dr. Carwright served as chief executive officer of Omnyx, LLC, a Joint Venture between GE Healthcare and the University of Pittsburgh Medical Center focused on the field of digital pathology. Prior to that, he was president of Molecular Diagnostics at GE Healthcare. He started his career at Abbott Labs in the Diagnostics Division where he worked for 24 years including jobs as divisional vice president of US Marketing and VP/GM of Abbott Molecular Diagnostics. He graduated from Dartmouth College and received a Ph.D. in chemistry from Stanford University. He has a Masters in Management from Northwestern University’s Kellogg School of Management.

Andre de Bruin

Mr. André De Bruin is an Independent Director of Nanosphere, Inc. Mr. De Bruin has more than 35 years of global healthcare industry experience spanning the bio-pharmaceutical, medical device and diagnostics markets. Most recently, Mr. de Bruin was the founder and chief executive officer of DuraPorts Inc., a manufacturer of steel and fabric structures. He also serves on the board of Directors of NxThera Inc., a medical device company based in St. Paul, MN, where he is Chairman of the Board. Prior to his retirement in 2004 as executive chairman of Quidel Corporation’s board of directors, Mr. de Bruin served as the company’s chief executive officer from 1998 until 2001. He was president and chief executive officer of Somatogen and was elected chairman in 1996. Prior to joining Somatogen, Mr. de Bruin was chairman, president and chief executive officer of Boehringer Mannheim Corporation, a global healthcare concern subsequently acquired by Hoffman-La Roche. Past experience includes advisory services for Ferrer, Freeman and Company, LLC and various boards of directors. Mr. de Bruin graduated from the University of Potchefstroom in South Africa, where he earned a B.S. in finance, economics and business.

Erik Holmlin

Dr. Erik Holmlin, Ph.D., is an Independent Director of Nanosphere, Inc., effective June 20, 2013. Dr. Holmlin is currently President and Chief Executive Officer of BioNano Genomics Inc., a commercial-stage company with a proprietary platform for genome mapping based on single molecule detection. From February 2010 to February 2011, Dr. Holmlin was an Entrepreneur in Residence at Domain Associates, LLC, a life sciences-dedicated venture capital firm, where one of his assignments was the role of President and Chief Executive Officer of GenVault Corporation, a provider of systems used for managing DNA collections. From July 2008 to November 2009 Dr. Holmlin was the Chief Commercial Officer of Exiqon A/S. In 2001, Dr. Holmlin led the formation of GeneOhm Sciences, Inc., a molecular diagnostics company that brought the first rapid tests for healthcare-associated infection (HAI) to market. In 2006, following GeneOhm’s acquisition by Becton Dickinson, Dr. Holmlin served as Vice President of Marketing and Development for Becton Dickinson Diagnostics until July 2008. Dr. Holmlin holds a Ph.D. in Chemistry from California Institute of Technology, MBA degrees from the Haas School of Business at UC Berkeley and the Columbia University School of Business and an AB degree in Chemistry from Occidental College.

Lorin Randall

Mr. Lorin Jeffry Randall is an Independent Director of Nanosphere, Inc. He has served as a member of Company's board of directors and the chairman of the audit committee since 2008. Mr. Randall is a financial consultant and also serves on the boards of the following healthcare companies: Tengion, Inc., Athersys, Inc. and Acorda Therapeutics, Inc. Mr. Randall previously served as senior vice president-chief financial officer of Eximias Pharmaceutical Corporation, a development stage provider of oncology therapeutics. Mr. Randall held the same position at i-STAT Corporation, a manufacturer of medical diagnostic devices, which was acquired by Abbott Laboratories in 2004. His career also includes senior management positions at CFM Technologies, a semiconductor manufacturing equipment company; Greenwich Pharmaceutical Corporation, a development stage provider of immune system disease therapeutics; and Surgilase, a provider of surgical lasers to hospitals and clinics. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.

Michael Ward

Mr. Michael J. Ward is an Independent Director of Nanosphere, Inc. Mr. Ward served as vice president at Lurie Investments, Inc. from September 2009 to January 2013 and as a director of investments from January 2013 to September 2013 where he was responsible for managing investment activities. Prior to joining Lurie Investments, Mr. Ward gained over 15 years of investment banking experience at Credit Suisse, Prudential Securities, Dresdner Kleinwort Wasserstein, BMO and Leerink Swann. Mr. Ward is a member of the board of directors of CytoPherx, Inc., an acute renal failure-focused therapeutic medical device company based in Ann Arbor, MI, and Aperion Biologics, Inc., an orthobiologics medical device company based in San Antonio, TX. Based on Mr. Ward’s familiarity with the Company as a former member of the investment team at Lurie Investments and his investment banking experience, the Board of Directors concluded that Mr. Ward has the requisite experience, qualifications, attributes and skill necessary to serve as a member of the Board of Directors.

Basic Compensation

Name Fiscal Year Total

Sheli Rosenberg

--

Michael McGarrity

2,669,870

J. Roger Moody

1,091,100

Kenneth Bahk

1,164,980

Kristopher Wood

--

Gene Cartwright

--

Andre de Bruin

--

Erik Holmlin

--

Lorin Randall

--

Michael Ward

--
As Of 30 Dec 2013
Search Stocks